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crucial to clinical decision making with this important class of
drugs.
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REPLY
I agree with Dr. Williams that simvastatin and lovastatin are more
prone than pravastatin to interact with drugs that inhibit cyto-
chrome P450 isozymes. But some of his other points do not survive
a careful reading of the scientific data.
First, Dr. Williams states that the interaction between prava-
statin and cyclosporine is “widely recognized” to involve
P-glycoprotein (PGP) and cites two references (1,2), but neither
study provides any scientific support for his claim. Indeed, the
limited available information suggests that pravastatin is a sub-
strate for other transporters such as canalicular multispecific
organic anion transporter (cMOAT) or organic anion-transporting
polypeptide (OATP) (3,4).
More importantly, even after years of frequent use of pravastatin
with cyclosporine, there is little evidence that the combination is
harmful (5–7), unlike lovastatin and simvastatin, where up to
20-fold increases in statin serum concentrations have been re-
ported and rhabdomyolysis has occurred (1,8–11). Moreover, even
if all statins were equally likely to interact with cyclosporine,
transplant patients receive other drugs as well, and the possibility
of the patient receiving other CYP3A4 inhibitors with lovastatin
or simvastatin creates additional concerns (10,11).
Dr. Williams further contends that myopathy following statin-
gemfibrozil combinations results from a pharmacodynamic inter-
action. This was commonly held, but we now know that gemfi-
brozil substantially increases serum concentrations of lovastatin
and simvastatin (12,13). Thus, the interaction is pharmacokinetic;
whether a simultaneous pharmacodynamic interaction exists is
speculative. Moreover, neither of the references Dr. Williams cited
to support myopathy following pravastatin-gemfibrozil contained
any actual cases of myopathy.
Dr. Williams cites large outcome trials, but such studies are
notoriously misleading in assessing drug interactions. For example,
the RALES trial found spironolactone plus angiotensin-
converting enzyme inhibitors safe and effective in treating severe
heart failure (14). Yet it is clear that in certain predisposed
patients—particularly those who get larger doses of spironolactone
in the presence of renal disease and diabetes—fatal hyperkalemia
can result (15–17). Thus it is with lovastatin and simvastatin where
life-threatening rhabdomyolysis has occasionally occurred owing to
drug interactions. The fact that serious or fatal drug interactions
are rare does not absolve us from preventing them when the
scientific evidence allows us to do so.
Finally, one can put statin drug interactions in the context of
what we have learned about drug interactions over the past 40
years. The poverty of proposing “class effects” for drug interactions
has been repeatedly confirmed, and it is extraordinarily rare for all
members of a drug class to interact homogeneously. Nonetheless,
it is convenient to say that we have insufficient information to be
certain that individual members of a drug class interact differently
from each other. If we held all drug interactions to that standard,
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we could rarely choose one member of a drug class over another in
order to reduce the risk of adverse interactions. But for many drug
classes, including the statins, we do have sufficient information to
choose members of the class that will reduce the drug interaction
risk in specific patients. To blur these differences is to put patients
at greater risk of a preventable adverse outcome.
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Efficacy of Simvastatin and
Ezetimibe in Treating Hypercholesterolemia
In a recent editorial published in JACC, Dr. Sacks summarized the
efficacy of co-administration of simvastatin and ezetimibe, a novel
cholesterol absorption inhibitor with a mechanism of action that is
complementary to statins (1,2). I appreciate the opportunity to
provide some additional data, likely not available at the time Dr.
Sacks drafted his editorial, to clarify some of the estimates
provided by Dr. Sacks (2).
Dr. Sacks took a hypothetical patient, with a pretreatment low
density lipoprotein cholesterol (LDL-C) level of 190 mg/dl, and
calculated LDL-C reductions and relative risk reduction (RRR)
estimates for simvastatin alone and simvastatin/ezetimibe co-
administration. It should be pointed out that the calculated LDL
reductions and RRR estimates for simvastatin alone and simvasta-
tin/ezetimibe in the editorial are actually too low and underesti-
mate the benefit of using ezetimibe with a statin compared to a
statin alone. This is due to the iterative use of the estimated 6%
reduction of LDL-C per doubling of simvastatin relative to
LDL-C values that were already reduced by simvastatin treatment.
The “6% rule” for incremental LDL-C lowering with doubling of
statin dose applies to the estimated reduction calculated relative to
the pre-statin LDL-C baseline (in this case, 190 mg/dl). The
correct sequence of values, therefore, would be as follows: 20 mg
simvastatin results in LDL-C of 125 mg/dl (34% reduction from
the base of 190 mg/dl); 40 mg simvastatin results in LDL-C of
114 mg/dl (40% reduction from 190 mg/dl); and 80 mg simvasta-
tin results in LDL-C of 102 mg/dl (46% reduction from 190
mg/dl). The RRR values would similarly decrease.
The same issue applies with respect to the calculation of
anticipated incremental lowering based on addition of ezetimibe.
Assuming a 14% reduction with ezetimibe, when ezetimibe is
added to the hypothetical patient already on 20 mg of simvastatin
with an LDL-C of 125 mg/dl, the reduction of LDL-C by 14%
(of 190, not 125 mg/dl) would result in a further decrease in
LDL-C of 26.6 mg/dl, bringing the patient to below the goal of
100 mg/dl without additional simvastatin titration.
The estimated efficacy from the above analysis is highly consis-
tent with the reported 27% reduction in LDL-C relative to
baseline (24% relative to placebo) observed when ezetimibe was
added to ongoing simvastatin therapy (3). The data from the
clinical trials of initiation of ezetimibe with both simvastatin and
atorvastatin indicate that 10 mg of ezetimibe added to either statin
produces incremental LDL-C lowering similar to that produced by
80 mg of the corresponding statin, an additional reduction that
would require an 8-fold increase in statin dosage to be achieved by
titration (4).
Dr. Sacks makes clearly important points about balancing
benefit and potential harm, including the fact that statin-related
adverse effects are dose dependent and occur more commonly at
the highest doses (5). Although the long-term safety experience
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